BR112015022390A8 - uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson - Google Patents
uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson Download PDFInfo
- Publication number
- BR112015022390A8 BR112015022390A8 BR112015022390A BR112015022390A BR112015022390A8 BR 112015022390 A8 BR112015022390 A8 BR 112015022390A8 BR 112015022390 A BR112015022390 A BR 112015022390A BR 112015022390 A BR112015022390 A BR 112015022390A BR 112015022390 A8 BR112015022390 A8 BR 112015022390A8
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- carbidopa
- composition
- levodopa
- preparation
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 3
- 229960004205 carbidopa Drugs 0.000 title abstract 2
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 title abstract 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 title 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 title 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 title 1
- 229960004502 levodopa Drugs 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 101150106671 COMT gene Proteins 0.000 abstract 1
- 102000006378 Catechol O-methyltransferase Human genes 0.000 abstract 1
- 108020002739 Catechol O-methyltransferase Proteins 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 229960003337 entacapone Drugs 0.000 abstract 1
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 238000007911 parenteral administration Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960004603 tolcapone Drugs 0.000 abstract 1
- MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/121—Ketones acyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Psychology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Otolaryngology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361779357P | 2013-03-13 | 2013-03-13 | |
| PCT/IL2014/050261 WO2014141261A1 (en) | 2013-03-13 | 2014-03-13 | Method for treatment of parkinson's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015022390A2 BR112015022390A2 (pt) | 2017-07-18 |
| BR112015022390A8 true BR112015022390A8 (pt) | 2019-11-26 |
Family
ID=50513395
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015022390A BR112015022390A8 (pt) | 2013-03-13 | 2014-03-13 | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson |
Country Status (21)
| Country | Link |
|---|---|
| US (4) | US20160022573A1 (https=) |
| EP (2) | EP3892266A1 (https=) |
| JP (2) | JP6472391B2 (https=) |
| KR (1) | KR102209353B1 (https=) |
| CN (2) | CN105209029A (https=) |
| AU (1) | AU2014229127B2 (https=) |
| BR (1) | BR112015022390A8 (https=) |
| CA (1) | CA2904838C (https=) |
| CL (1) | CL2015002641A1 (https=) |
| DK (1) | DK2968218T3 (https=) |
| ES (1) | ES2889626T3 (https=) |
| HR (1) | HRP20211442T1 (https=) |
| HU (1) | HUE056006T2 (https=) |
| IL (1) | IL266648B (https=) |
| MX (1) | MX365206B (https=) |
| PL (1) | PL2968218T3 (https=) |
| PT (1) | PT2968218T (https=) |
| RU (2) | RU2018144700A (https=) |
| SG (2) | SG10201911731YA (https=) |
| WO (1) | WO2014141261A1 (https=) |
| ZA (1) | ZA201507621B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010134074A1 (en) | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| EP2640358B1 (en) | 2010-11-15 | 2018-01-03 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
| EP2640370B1 (en) | 2010-11-15 | 2018-03-14 | Neuroderm Ltd | Compositions for transdermal delivery of active agents |
| ES2967693T3 (es) * | 2014-03-13 | 2024-05-03 | Neuroderm Ltd | Composiciones del inhibidor de la dopa descarboxilasa |
| US10258585B2 (en) | 2014-03-13 | 2019-04-16 | Neuroderm, Ltd. | DOPA decarboxylase inhibitor compositions |
| PT3782617T (pt) | 2014-09-04 | 2024-02-29 | Lobsor Pharmaceuticals Ab | Composições farmacêuticas de gel compreendendo levodopa, carbidopa e entacapona |
| RU2743347C2 (ru) | 2014-10-21 | 2021-02-17 | Эббви Инк. | Пролекарства карбидопа и l-dopa и их применение для лечения болезни паркинсона |
| MA41377A (fr) | 2015-01-20 | 2017-11-28 | Abbvie Inc | Gel intestinal de lévodopa et de carbidona et procédés d'utilisation |
| WO2017039525A1 (en) * | 2015-09-04 | 2017-03-09 | Lobsor Pharmaceuticals Aktiebolag | Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor |
| WO2017070293A1 (en) * | 2015-10-20 | 2017-04-27 | Ironwood Pharmaceuticals, Inc. | Phosphodiesterase 9 inhibitor and levodopa therapy |
| EP3275433A1 (en) * | 2016-07-29 | 2018-01-31 | Som Innovation Biotech S.L. | Sustained release composition comprising micronized tolcapone |
| HUE054268T2 (hu) * | 2017-06-05 | 2021-08-30 | Dizlin Pharmaceuticals Ab | Levodopa infúziós oldat |
| WO2019097120A1 (en) * | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| CN111655243A (zh) | 2018-01-29 | 2020-09-11 | 乔纳森·萨克纳-伯恩斯坦 | 在人类神经系统疾病中调节多巴胺的方法 |
| EP3773532A4 (en) * | 2018-03-29 | 2022-11-02 | Avion Pharmaceuticals, LLC | FRACTIONAL LEVODOPA DOSAGE AND USE |
| CN113015531A (zh) | 2018-11-15 | 2021-06-22 | 艾伯维公司 | 用于皮下施用的药物调配物 |
| CN111701024B (zh) * | 2020-05-26 | 2022-05-24 | 上海京新生物医药有限公司 | 一种左旋多巴制剂及其制备方法及其应用 |
| US20230181508A1 (en) * | 2020-08-31 | 2023-06-15 | Purdue Pharma L.P. | Compositions and methods for levodopa delivery |
| US11331293B1 (en) | 2020-11-17 | 2022-05-17 | Neuroderm, Ltd. | Method for treatment of Parkinson's disease |
| US11844754B2 (en) | 2020-11-17 | 2023-12-19 | Neuroderm, Ltd. | Methods for treatment of Parkinson's disease |
| US11213502B1 (en) | 2020-11-17 | 2022-01-04 | Neuroderm, Ltd. | Method for treatment of parkinson's disease |
| WO2023282900A1 (en) * | 2021-07-08 | 2023-01-12 | Morehouse School Of Medicine | Method and system of diagnosing and treating neurodegenerative disease and seizures |
| US12161612B2 (en) | 2023-04-14 | 2024-12-10 | Neuroderm, Ltd. | Methods and compositions for reducing symptoms of Parkinson's disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US4832957A (en) * | 1987-12-11 | 1989-05-23 | Merck & Co., Inc. | Controlled release combination of carbidopa/levodopa |
| FI109453B (fi) * | 1999-06-30 | 2002-08-15 | Orion Yhtymae Oyj | Farmaseuttinen koostumus |
| EA013161B1 (ru) * | 2005-06-08 | 2010-02-26 | Орион Корпорейшн | Дозированная форма для перорального применения |
| TR200806646A2 (tr) * | 2008-09-03 | 2009-06-22 | Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. | Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar |
| WO2010134074A1 (en) * | 2009-05-19 | 2010-11-25 | Neuroderm Ltd | Compositions for continuous administration of dopa decarboxylase inhibitors |
| EP2640358B1 (en) * | 2010-11-15 | 2018-01-03 | Neuroderm Ltd | Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same |
-
2014
- 2014-03-13 PT PT147181770T patent/PT2968218T/pt unknown
- 2014-03-13 RU RU2018144700A patent/RU2018144700A/ru not_active Application Discontinuation
- 2014-03-13 SG SG10201911731YA patent/SG10201911731YA/en unknown
- 2014-03-13 WO PCT/IL2014/050261 patent/WO2014141261A1/en not_active Ceased
- 2014-03-13 JP JP2015562555A patent/JP6472391B2/ja active Active
- 2014-03-13 EP EP21176202.6A patent/EP3892266A1/en not_active Withdrawn
- 2014-03-13 PL PL14718177T patent/PL2968218T3/pl unknown
- 2014-03-13 US US14/774,938 patent/US20160022573A1/en not_active Abandoned
- 2014-03-13 BR BR112015022390A patent/BR112015022390A8/pt not_active Application Discontinuation
- 2014-03-13 CA CA2904838A patent/CA2904838C/en active Active
- 2014-03-13 AU AU2014229127A patent/AU2014229127B2/en active Active
- 2014-03-13 KR KR1020157028984A patent/KR102209353B1/ko active Active
- 2014-03-13 CN CN201480027268.2A patent/CN105209029A/zh active Pending
- 2014-03-13 ES ES14718177T patent/ES2889626T3/es active Active
- 2014-03-13 RU RU2015143112A patent/RU2677278C2/ru active
- 2014-03-13 DK DK14718177.0T patent/DK2968218T3/da active
- 2014-03-13 CN CN201911315631.1A patent/CN110935026A/zh active Pending
- 2014-03-13 HU HUE14718177A patent/HUE056006T2/hu unknown
- 2014-03-13 SG SG11201507538UA patent/SG11201507538UA/en unknown
- 2014-03-13 HR HRP20211442TT patent/HRP20211442T1/hr unknown
- 2014-03-13 EP EP14718177.0A patent/EP2968218B1/en active Active
- 2014-03-13 MX MX2015012561A patent/MX365206B/es active IP Right Grant
-
2015
- 2015-09-11 CL CL2015002641A patent/CL2015002641A1/es unknown
- 2015-10-13 ZA ZA2015/07621A patent/ZA201507621B/en unknown
-
2019
- 2019-01-22 JP JP2019008215A patent/JP6625773B2/ja active Active
- 2019-05-15 IL IL266648A patent/IL266648B/en active IP Right Grant
-
2020
- 2020-05-18 US US16/876,911 patent/US20210093560A1/en not_active Abandoned
-
2022
- 2022-03-18 US US17/698,189 patent/US20230047847A1/en not_active Abandoned
-
2024
- 2024-07-05 US US18/764,647 patent/US20250177292A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112015022390A8 (pt) | uso de carbidopa, levodopa e um inibidor de comt para a preparação de uma composição para tratamento de doença de parkinson | |
| CY1120005T1 (el) | Συνεχης χορηγηση αναστολεων l-ντοπα, αποκαρβοξυλασης ντοπα, αναστολεων κατεχολ-ο-μεθυλ τρανσφερασης και συνθεσεις αυτων | |
| CL2020000382A1 (es) | Composiciones de aminoácidos para el tratamiento de enfermedad hepática. | |
| BR112017005693A2 (pt) | método para tratar e/ou prevenir uma doença hepática, e, composição farmacêutica. | |
| BR112019002538A2 (pt) | uso de uma composição farmacêutica compreendendo um modulador alostérico, uso de uma composição farmacêutica compreendendo garboxadol ou um sal farmaceuticamente aceitável do mesmo, e composição farmacêutica para a administração parenteral | |
| CO2018003168A2 (es) | Moduladores de la expresión de kras | |
| BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
| BR112017008198A2 (pt) | pró-fármacos de carbidopa e l-dopa e métodos de uso | |
| BR112014009528A8 (pt) | métodos e composições para tratar eritropoiese ineficaz | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| BR112016021034A8 (pt) | composição farmacêutica, uso da mesma e kit | |
| BR112014006030A2 (pt) | formulação, uso de uma formulação, e, processo para a preparação de uma formulação | |
| BR112014030813A2 (pt) | tratamento de efeitos colaterais de desordens motoras e de movimento associadas com tratamentos de doenças parkinson | |
| AR124078A1 (es) | Método para el tratamiento de la enfermedad de parkinson | |
| BR112018007625A2 (pt) | composição antibacteriana combinada e regime antibacteriano de curto prazo | |
| BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
| BR112014029954A2 (pt) | tratamento de tumores sólidos usando coenzima q10 | |
| BR112017011168A2 (pt) | medicamentos para retardar a doença de parkinson | |
| BR112013024424A2 (pt) | recipiente, dispositivo de fixação, sistema de fixação e aplicador de injeção | |
| BR112014019399A2 (pt) | métodos de tratamento da fibrose | |
| BR112016004118A2 (pt) | uso de inibidores da acetil-coa carboxilase para tratamento de acne vulgar | |
| BR112017000312A2 (pt) | sistema de tratamento da saúde bucal para a aplicação de fosfato de cálcio amorfo, uso de um ou mais aminoácidos básicos, composição, e uso de um ou mais aminoácidos em um sistema de tratamento da saúde bucal | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| BR112017014914A2 (pt) | terapia combinada para hipertensão pulmonar | |
| AR106313A1 (es) | Combinación de levodopa deuterada con carbidopa y opicapona para el tratamiento de enfermedad de parkinson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B25G | Requested change of headquarter approved |
Owner name: NEURODERM LTD (IL) |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021 |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |